US-based Gilead Sciences has roped in four Indian pharmaceutical companies to develop and market three new generic HIV/AIDS drugs in over 100 countries. The drugs are currently in final stages of clinical development. CNBC-TV18's Appaji Reddem and Ashwin Mohan delve deeper.
first published: Jul 12, 2011 09:45 pm
A collection of the most-viewed Moneycontrol videos.
You are already a Moneycontrol Pro user.

